Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

175 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Oral administration of MA-2029, a novel selective and competitive motilin receptor antagonist, inhibits motilin-induced intestinal contractions and visceral pain in rabbits.
Sudo H, Yoshida S, Ozaki K, Muramatsu H, Onoma M, Yogo K, Kamei K, Cynshi O, Kuromaru O, Peeters TL, Takanashi H. Sudo H, et al. Among authors: peeters tl. Eur J Pharmacol. 2008 Mar 10;581(3):296-305. doi: 10.1016/j.ejphar.2007.11.049. Epub 2007 Nov 28. Eur J Pharmacol. 2008. PMID: 18164286
Motilin.
Poitras P, Peeters TL. Poitras P, et al. Among authors: peeters tl. Curr Opin Endocrinol Diabetes Obes. 2008 Feb;15(1):54-7. doi: 10.1097/MED.0b013e3282f370af. Curr Opin Endocrinol Diabetes Obes. 2008. PMID: 18185063 Review.
An orally active motilin receptor antagonist, MA-2029, inhibits motilin-induced gastrointestinal motility, increase in fundic tone, and diarrhea in conscious dogs without affecting gastric emptying.
Ozaki K, Onoma M, Muramatsu H, Sudo H, Yoshida S, Shiokawa R, Yogo K, Kamei K, Cynshi O, Kuromaru O, Peeters TL, Takanashi H. Ozaki K, et al. Among authors: peeters tl. Eur J Pharmacol. 2009 Aug 1;615(1-3):185-92. doi: 10.1016/j.ejphar.2009.04.059. Epub 2009 May 13. Eur J Pharmacol. 2009. PMID: 19445919
175 results